What are you looking for? License Status VerificationAnnual/Quarterly ChecklistsFraud AssessmentsCompany LicensingRenewalsStatutory DepositsFeesApplying for Admission & ApplicationsLife and Health DivisionProduct FilingPharmacy Benefit Managers (PBM) Reports, New Mexico Health Access Survey, and BriefsContracted and External ReportsOSI Health Insurance BriefsThe 2023 New Mexico Health Access SurveyResource BinderRequest for Confidential StatusContinuous Quality ImprovementUtilization ManagementMember GrievanceHealth Rate ReviewProvider GrievanceMonthly Member EnrollmentHealth Care Affordability FundProvider CredentialingDental Provider CredentialingCoverage for Individuals with Diabetes (HB53)Network AdequacyManaged Health Care Compliance DeadlinesMental Health ParityDebt Collection Protection Act - Provider ResourceMiscellaneous Resource Binder ContentSmall Business Health Insurance Premium Relief InitiativePrescription Drug Price TransparencyVaccine Purchasing ActGuidance for CarriersProperty & CasualtyFinancial RegulationFinancial and Market Conduct Examinations - ArchiveAccredited ReinsurersFinancial StatementsFinancial Statements ArchiveFinancial Examinations Financial Examinations ArchiveTitle Insurance Forms & TablesASR USR Schedules & InstructionsStatistical ReportsIndividuals and AgenciesContinuing Education (CE)Criminal Offense Contact Rolanda Pana Phone: (505) 795-1495 rxtransparency@osi.nm.gov OSI Events Calendar View our calendar of events During the 2023 Legislative Session, the New Mexico State Legislature passed House Bill 33, the Prescription Drug Price Transparency Act. This legislation mandates the New Mexico Office of Superintendent of Insurance (OSI) to collect data from Drug Manufacturers, Pharmacy Services Administrative Organizations (PSAOs), authorized health insurers, and Pharmacy Benefit Managers (PBMs) regarding drug prices and sales. The law also requires OSI to report annually to legislative committees and the public. To fulfill this mandate, OSI will evaluate whether reporting entities meet the established reporting standards, analyze the data, and assess compliance with the Prescription Drug Price Transparency submission criteria. For additional information on these requirements, please refer to NMSA 1978, Section 59A-59A. Prescription Drug Price Transparency Reporting Tool Prescription Drug Price Transparency Act Submission Guidance 2026 (updated 02-24-2026) Prescription Drug Price Transparency Legislative Report 2025
June 26, 2026 Bulletins MEDICAL MALPRACTICE PREMIUM REDUCTION AMENDED BULLETIN 2026-010: The New Mexico State Legislature appropriated $5 million to the New Mexico Office of Superintendent of Insurance (OSI) to address medical malpractice insurance costs for individual providers. The appropriation was part of a supplemental appropriation package passed in 2025. This one-time appropriation directs OSI to provide a premium subsidy for private medical malpractice insurance policies. […] Read More
June 12, 2026 Announcements NOTICE OF PRESCRIPTION DRUG PRICE TRANSPARENCY ANNUAL MEETING The Office of the Superintendent of Insurance will hold its annual public meeting to present and discuss the findings and recommendations contained in the 2025 Prescription Drug Price Transparency legislative report. The purpose of this meeting is to inform the public of the report’s contents and to provide an opportunity for public comments and questions. […] Read More
